

Recent progress on metal-based nanomaterials for cancer radiosensitization

Xiu Zhao¹, Jun Li¹, Qiongwei Wang¹, Zhenzhong Zhang¹, Junjie Liu¹, and Jinjin Shi¹

¹Zhengzhou University

March 13, 2023

Abstract

Radiotherapy is a mainstay treatment for malignant tumors in clinical. However, enhancing radiation damage to tumor cells meanwhile sparing normal tissues is still a great challenge in radiotherapy. Nanomaterials with high atomic number (Z) values are promising radiosensitizers by promoting the radiation energy deposition in irradiated tumor cells, thus enhancing the therapeutic ratio of radiotherapy. In this review, we described the mechanisms of high-Z element radiosensitizers and systematically summarized the recent progress on metal-based nanomaterials, including high-Z metal nanoparticles, metal-organic frameworks (MOFs) and other high-Z-containing nanomaterials. Finally, further potential and challenges in this field were discussed.

Recent progress on metal-based nanomaterials for cancer radiosensitization

Xiu Zhao,^a Jun Li,^a Qiongwei Wang,^a Zhenzhong Zhang,^{*,a,b,c} Junjie Liu^{*,a,b,c} and Jinjin Shi^{*,a,b,c}

^a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China^b Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Henan Province, China^c Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001, China

Comprehensive Summary

Radiotherapy is a mainstay treatment for malignant tumors in clinical. However, enhancing radiation damage to tumor cell

Keywords

Radiotherapy | Nanoradiosensitizers | High-Z metal | Energy deposition | Nanomaterial

Contents

1. Introduction 2
2. High-Z metal nanoparticles for radiosensitization 2
 - 2.1. Gold (Au)-based metal NPs 2
 - 2.2. Bismuth (Bi)-based metal NPs 3

- 2.3. Gadolinium (Gd)-based metal NPs 3
- 2.4. Iridium (Ir)-based metal NPs 3 Page No.
- 3. Metal-Organic Frameworks 5
- 3.1. Hafnium (Hf)-based nMOFs 5
- 3.2. Zirconium (Zr)-based nMOFs 6
- 3.3. Other types of metal-based nMOFs 6
- 4. Other high-Z-containing nanomaterials 6
- 5. Conclusions and Perspectives 7
- 1. Introduction

As the first-line clinical management of malignant tumors, approximately 50% of cancer patients receive radiotherapy (RT),^[1-3] which is usually used as an adjuvant treatment modality prior to surgery to shrink the tumor, or postoperative prevention of residual tumor recurrence.^[4] Radiotherapy mainly uses X-rays to kill cancer cells. The high-energy radiation can directly cause DNA damage, or react with water molecule to produce reactive oxygen species (ROS), indirectly damage DNA. The accumulated DNA breaks ultimately induce tumor cell necrosis or apoptosis.^[5-6] Despite radiotherapy has made some progress in suppressing tumor growth, tumor cells often show innate or acquired resistance to ionizing radiation. For example, the soft tumor tissues have low energy absorption coefficient, which usually requires a high radiation dosage and cause unavoidable damage to neighboring normal tissues, thus reducing the long-term life quality of patients.^[7-8] In addition, the hypoxic tumor microenvironment, strong antioxidant system in tumor cells and enhanced DNA damage response are not conducive to effective DNA damage, which greatly reduce radiotherapy efficiency and ultimately result in treatment failure.^[9-12] Thus, it is crucial to explore effective strategies for enhancing cancer radiotherapy.

Currently, impressive advances have been made in radiosensitizers for boosting tumor radiosensitivity. Especially, due to the intrinsic radiosensitive activities, chemical inertness, and good biocompatibility, high-Z element-containing nanomaterials are promising radiosensitizers and have been successfully employed for improving the RT therapeutic efficacy.^[13-15] High-Z radiosensitizers possess high X-ray coefficient, which is significantly higher than that of tumor soft tissue. When tumor cells are exposed to high-energy radiation, high-Z atoms are excited by high-energy elements to collide due to the larger electron density. A large number of secondary charged particles and radiated photons are released, including Photoelectrons, Compton electrons and Auger electrons, which make a major contribution to energy conversion and deposition in the irradiated tumor tissues.^[16] The dose-enhancing effect amplifies the damage of DNA directly, or producing more ROS by dissociating water to enhance the radiation sensitivity of cancer cells. Previously, many researchers have focused on the noble metal nanoparticles with intrinsic radiosensitive activities and good biocompatibility, particularly gold nanoparticles (Au NPs)-mediated radiosensitization. With the rapid development of nanotechnology, a large number of multifunctional high-Z element-containing nanomaterials with synthetic tenability and drug loading capacity are continuously reported, which broaden the horizon of this field and accelerate the development of metal-based radiosensitizers. In this review, we highlight the progress of metal-based nanoradiosensitizers. Based on the structures, we divide these nanoradiosensitizers into three categories, namely, high-Z metal nanoparticles, metal-organic frameworks (MOFs), and other high-Z-containing nanomaterials. Finally, we further discuss the current challenges of metal-based nanoradiosensitizers. We hope that this review article can help researchers understand the latest progress of metal-based nanoradiosensitizers and encourage all of us to make new breakthroughs in this field in the future work.

2. High-Z metal nanoparticles for radiosensitization

So far, many high-Z metal nanoparticles have been used as radiosensitizers to improve the efficacy of RT

through a rationale of energy deposition. They possess good chemical stability, low toxicity and morphological diversity. Several investigations about various high-Z metal nanoparticles have been made to improve the radiosensitivity of tumor cells (Table. 1), including metal nanoparticles of Au,^[17-35] Hf,^[14, 36] Pt,^[37] Bi,^[38-43] Ir,^[44-46] Gd,^[47-53] Ta,^[54] Ga,^[49, 55] and Te,^[55, 56] etc.

2.1. Gold (Au)-based metal NPs

Au nanoparticles (Au NPs) are commonly researched radiosensitizers. In recent years, there has been a rapid development in the research on radiation sensitization of Au NPs. The regulation of the size, structure and surface modification of nanoparticles can optimize the efficiency of radiation sensitization and tumor treatment to varying degrees. For example, Coulter et al. prepared polystyrene-supported gold nanoparticles (AuNP@PS) for increasing its stability in physiological conditions. Compared with free Au NPs, the composite AuNP@PS showed enhanced radiation efficiency at a dose of 4 Gy, which proved the radiation enhancement of the polymer support material.^[27] Wang et al. modified ultra-small gold nanoparticles with a tumor microenvironment (TME)-responsive multifunctional peptide (Tat-R-EK) *via* the Au-S bonds between gold and thiol groups from cysteine on Tat peptide. The Au NPs exhibited good stability and cathepsin B-responsive release of Tat-modified gold nanoparticles, leading to selectively targeting tumor cells. Such a formation improved radiotherapy efficiency by enhancing DNA damage. Moreover, it was easily cleared by the kidney profiting from the ultra-small size.^[26] Liu et al. reported an acid-triggered gold nanoparticles (GNPs) aggregation strategy for RT enhancement. GNPs were modified with two peptides grafting 2, 3-Dimethylmaleic anhydride, termed as GNPs-A and GNPs-B, respectively. When arriving at the acidic tumor microenvironment (pH 6.5), the negatively charged GNPs-B was reversed to a positive charge state, and formed a larger GNPs aggregate with the negatively charged GNPs-A through electrostatic interaction, which promoted GNPs to effectively accumulate at the tumor tissue and meanwhile improved its *in vivo* photoacoustic imaging ability. More importantly, the sensitizer enhancement ratio (SER) value of the GNPs aggregation (1.73) in MCF-7 cells was much higher than that of single GNPs (1.16), greatly improved the radiosensitive efficiency.^[28] In addition, Yang et al. prepared a GSH-responsive Au-MnO Janus nanovesicle (JNP Ve) by being self-assembled with a NIR-II dye IR1061. JNP Ve could be degraded into small Au NPs and manganese ion (Mn²⁺) in response to GSH, which not only allowed for deep penetration of Au NPs but also produced more ROS through Mn²⁺-mediated Fenton-like reaction, significantly enhancing RT efficacy. Meanwhile, the quenched IR1061 fluorescence was restored for image-guided tumor detection.^[20] As a typical example, Song et al. observed that a multifunctional photocatalytic driven dandelion nanosystem composed of plasma amorphous TiO₂ components and Au nanorods could significantly enhance the radiotherapy effect due to the heterogeneous structure of electron-hole pairs, which enhanced drug accumulation through autonomous navigation.^[18]

2.2. Bismuth (Bi)-based metal NPs

Bi-based nanoparticles are one of the hottest materials in radiotherapy. For example, Zhao et al. provided a representative example that met both radiosensitization and biosafety requirements. Ultra-small BiOI quantum dots (QDs) were synthesized *via* a simple two-step method. Under X-ray irradiation, BiOI QDs with high-Z element could also generate *OH by decomposing overexpressed hydrogen peroxide (H₂O₂) for radiation enhancement. In addition, BiOI QDs showed good biocompatibility, which were rapidly cleared by renal metabolic pathway and showed low accumulation in liver and spleen.^[41] Chen et al. synthesized plasmonic Bi/Bi₂O₃-x by in situ fabrication of Bi₂O₃-x on Bi *via* a hydrothermal method and modified with the folate for tumor targeting. The oxygen vacancy defects allowed Bi/Bi₂O₃-x to absorb near-infrared light for combined photothermal therapy and radiotherapy. Moreover, Bi/Bi₂O₃-x showed excellent photoacoustic imaging ability for deep tissues.^[39] Zhang et al. recently reported a biomimetic RT sensitization platform by combining cyanobacterial and 2D bismuthine. Upon the 660 nm laser and X-ray irradiation, cyanobacteria could produce oxygen *via* photosynthesis to relieve hypoxia in tumor tissue, further amplifying Bi-mediated radiation sensitization.^[40] Recently, bacteria with excellent tumor targeting have attracted wide attention and are used as drug delivery carriers due to the easy surface modification. As a representative example, Zhang et al. developed a Bi₂S₃ nanoparticles-loaded engineered Escherichia coli MG1655 (Bac@BNP).

Bac@BNP could effectively accumulate at tumor tissues and released Bi_2S_3 nanoparticles in response to the matrix metalloproteinase-2 (MMP-2). The produced cytolytic A (ClyA) protein by Bac could regulate the cell cycle, accompanied with the radiosensitization effect of Bi_2S_3 for enhanced tumor radiotherapy (Figure 1A).^[38] Therefore, nanomaterials with Bi manifest the great hope for radiosensitization.

2.3. Gadolinium (Gd)-based metal NPs

Similar to gold, metal nanomaterials with Gd have been developed to promote radiosensitization. For example, by using the virus-like silica (V-Si) as the template, Zhang et al. constructed a biodegradable Gd-based hollow virus-like nanoparticle loaded with second near-infrared dye ICG and then modified with cyclic RGD peptide (R&HV-Gd@ICG). The Gd-based nanoparticles showed excellent tumor targeting capability and enhanced RT efficacy by producing numerous ROS and serious DNA damage. Otherwise, its fluorescent imaging capability allowed tumors to be visualized, which was of significance in breast conservation surgery.^[57] In addition, Zhang et al. synthesized a RVG29-modified gadolinium-based biodegradable nanocapsule for NIR-II FI/MRI-guided glioblastoma (GBM) treatment, with PLGA as the carrier loading Gd_2O_3 : Nd^{3+} nanodots, MnO_2 and chemotherapy drug TMZ. After the nanocapsule crossed the blood brain barrier and aggregated to tumor tissue owing to the RVG29 peptide, the high-Z-based nanocapsule released TMZ and produced O_2 in response to pH for enhanced radio-chemotherapy and remarkably inhibited the growth of the tumors.^[47] As a paradigm, Xie et al. developed an ultrafine gadolinium-carbon quantum dots (Gd@Cdots) *via* a hydrothermal method, which had minimal Gd leakage and low toxicity due to the biological inertness of carbon and rapid clearance from body. Moreover, Gd@Cdots could produce hydroxyl radical in H1299 cells under X-ray irradiation due to the photoelectric effect of Gd and surface catalytic effect of carbon.^[51] Consequently, Gd-based metal nanoparticles can be envisioned to a certain extent as the effective radiosensitizers to support RT.

2.4. Iridium (Ir)-based metal NPs

Iridium (Ir, $Z = 77$) with high stability and high biocompatibility has hold much attention in RT field over recent decades. For instance, Liu et al. successfully synthesized Ir nanocrystals (IrNCs) *via* a chemical reduction and were encapsulated with PEG-modified liposomes for preventing being toxified by thiol biomolecules. According to the photoacoustic images *in vivo*, Ir@liposome showed better accumulation and retention ability compared with Ir NPs. Moreover, IrNCs showed catalase-mimicking activity upon NIR laser to relieve tumor hypoxia, combined with the radiosensitization of high-Z element Ir, greatly improved the efficacy of radiotherapy.^[46] Xu et al. also reported an ultra-small Ir nanocrystals of < 5 nm, which was decorated with RGD and TAT peptides for double targeting of tumor cell membrane and cell nucleus. It had been demonstrated that the high-Z element Ir effectively accumulated in the nucleus and produced extensive DNA damage under X-rays in 4T1 cells, indicating the amazing sensitization effect. Fortunately, Ir nanocrystals was not only a good radiotherapy sensitizer, but also had good photothermal conversion ability, which provides great potential for photothermal synergistic therapy (Figure 1B).^[45]




Figure 1 (A) Mechanism diagram of Bac@BNP-mediated radiosensitization. Reprinted with permission,^[38] Copyright 2022, American Chemical Society. (B) Illustration of tumor cell membrane and cell nucleus dual-targeting process of Ir-R/T NCs. Reprinted with permission,^[45] Copyright 2019, Wiley-VCH.

Table 1 High-Z metal nanoparticles for radiosensitization

Element	Size (nm)	Shape
Au Au Au Au Au Au	4.0-6.3 110 4.5 ± 0.7 < 5.5 28.2 Length: 93, Diameter: 16	Nanocluster Nanostar Spherical Spherical
Bi	150	Nanosheet
Bi	100	Spherical
Bi	3	Spherical
Bi	200	Layered Nanosheet
Bi	190	Spherical
Gd	140	Spherical surrounded by nanospike
Gd	3	Spherical
Gd	84	Nanocapsule
Gd	< 5	Spherical
Pt	6.64 ± 1.3	Spherical

Element	Size (nm)	Shape
Ir	< 5	Octahedral
Ir	3.3	Spherical
Te	180	Nanosword
Ga	110	Spherical
Hf	213.2 ± 15.8	Lamellar
Ta	70	Spherical

Table 2 Metal-based metal-organic frameworks for radiosensitization

Element	Size (nm)	Surface modification	Responsiveness	Cell line/model	X-ray dose	Refs
Hf	100	-	-	MC38	1 Gy	[70]
Hf	212.9 ± 4.2	αCD47	-	CT26	2 Gy	[71]
Hf	80-150	PEG	-	4T1	6 Gy	[72]
Hf Hf	190 98.1 ± 4.1	cGAMP -	High phosphate -	MC38 MC38	2 Gy 2 Gy	[75] [76]
Hf	100	-	-	MC38	2 Gy	[77]
Hf	95 ± 18	-	-	KYSE 150	6 Gy	[68]
Hf	100	PEG	-	HeLa	4 Gy	[69]
Hf	100	CPG	-	MC38	1 Gy	[78]
Hf	72	-	-	SQ20B	1 Gy	[79]
Hf	44 ± 14	DDR inhibitors	-	4T1	4 Gy	[80]
Zr	62	QU	PH	A549	8 Gy	[87]
Zr Zr Th Bi	80 250 80	AuNPs	High	U87MG	8 Gy 8 Gy 2	[88] [89] [93]
	109 ± 5	AuNPs - -	phosphate - -	MDA-MB-231 CT26 TRAMP-C2	Gy 1 Gy	[94]
Ln	250	-	-	HeLa	4 Gy	[95]

3. Metal-Organic Frameworks

Nanoscale metal organic frameworks (nMOFs) represent a class of hybrid materials assembled from tunable metal clusters and functional organic bridging ligands. Over the past decade, nMOFs have emerged as a new type of material that proposed for biomedical applications due to the synthetic tenability, simple synthesis process, high porosity, large surface area and good biocompatibility.^[58-62] Notably, high-Z-based nMOFs have shown potential antitumor ability by increasing local radiation dose deposition and generating highly cytotoxic ROS upon x-ray irradiation. Compared to traditional metal-based nanoradiosensitizer (e.g., Au, Bi₂S₃ and HfO₂), nMOFs present several advantages including the improved drug loading capacity and good biodegradability, which have emerged as a promising radiosensitizer platform. Table 2 summarized the combination of different metal ions to form different nMOFs for radiosensitization. Herein, we took the most popular nMOFs containing the metal element (hafnium, zirconium, lanthanide) as paradigms to describe a series of coordination frameworks of metal-based radiosensitizers for improving the efficiency of radiotherapy.

3.1. Hafnium (Hf)-based nMOFs

In recent years, hafnium-based nanoscale metal-organic frameworks (Hf-nMOFs) have received great attention in the radiosensitization field owing to their excellent X-ray conversion and energy absorption ability.^[63-67] For example, Cheng et al. reported a Hf-based MOF (UiO-66-NH₂(Hf)) of about 100 nm

for achieving radiosensitization, which showed a good anti-tumor effect *in vitro* and *in vivo* by increasing the X-ray absorption in tumor cells.^[68] Despite the success of radiotherapy, the single sensitizing effect is still not satisfactory. Multimode combined therapy has become a popular trend in recent years. As showed in Figure 2A, Bu et al. prepared the Fe³⁺-functionalized Hf-nMOFs (Hf-BPY-Fe) for providing the full-process radiation sensitivity by magnifying ^{*}OH formation to obtain better radiotherapy efficiency.^[69] Specifically, Hf⁴⁺ in Hf-BPY-Fe (Hf-nMOFs) could produce substantial amounts of high-energy electrons when received high-energy radiation, which could convert H₂O to ^{*}OH partially and, besides, formed an environment of electron enrichment. The electron enrichment environment created by nMOFs could accelerate the reduction of Fe³⁺ to Fe²⁺, which further promoted the generation of ^{*}OH in the process of Fenton reaction to effectively destroy DNA molecules. The RT enhancement mechanism of this Hf-nMOFs was illustrated in Figure 2B. In general, this work realized CDT and RT synergistic therapy. In addition, there were lots of works using the strategy that combined a method based on radiotherapy and photodynamic therapy (RT-RDT), which could significantly decrease the tumor cell survival and delay tumor growth.^[70-77] As a representative example, Lin et al. prepared a novel nMOF (Hf-DBBF-Ir) as an *in situ* cancer vaccine by rationally integrating high-Z metal Hf₆ secondary building units and photosensitizing ligands DBBF-Ir and meanwhile loading immune adjuvant CpG *via* electrostatic interactions.^[78] Mechanistically, after intratumoral administration, the Hf clusters could effectively absorb X-ray to generate ^{*}OH through radiolysis and transferred energy to adjacent photosensitizing ligands to generate ¹O₂, resulting in the release of tumor associated antigens, danger-associated molecular patterns and CpG for antigen presenting cells (APCs) upon X-ray irradiation. In general, this strategy of using RT-RDT effectively activated systemic antitumor immunity through Hf-nMOFs and promoted tumor elimination. For another example, Lu et al. constructed Hf-based nMOFs composed of Hf clusters and DBP or TBP-based photosensitizer ligands for RT-RDT therapy, which could efficiently eradicate primary and distant tumors under a low dose of X-rays when combined with checkpoint blockade agent (IDOi).^[79] In addition, Sun et al. prepared two DNA damage repair (DDR) inhibitors-loaded nMOF (TB@Hf-BDC-PEG), which restored the sensitivity of tumor cells to radiotherapy and improved the apoptosis rate of tumor cells *via* Hf-mediated ROS enhancement and the block of DNA damage repair pathway of tumor.^[80]

3.2. Zirconium (Zr)-based nMOFs

Zirconium (Zr)-based nMOFs have received great attention in recent years.^[81-85] It is noteworthy that it has also shown great potential in the field of radiotherapy sensitization.^[86] Meng et al. prepared Zr-MOF through the coordination of Zr²⁺ and 1, 4-benzenedicarboxylic acid and loaded with quercetin (QU) (Zr-MOF-QU). Under tumor acid microenvironment, Zr-MOF was degraded, releasing Zr²⁺, 1, 4-benzenedicarboxylic acid and QU. 1,4-benzenedicarboxylic acid could inactive carbonic anhydrase IX by binding to the active site of Zn²⁺ to relieve tumor hypoxia, which cooperated with QU for a dual radiosensitization effects and thus improved the efficiency of radiotherapy (Figure 2C).^[87] A hybrid nanomaterial based on Zr-based MOF and Au NPs reported by Chen et al. significantly inhibited tumor growth with minimal systemic toxicity, opening up a new prospect for the next generation of therapeutic nanomaterials.^[88] Zr-cluster and Au NPs as radiosensitizers had high X-ray attenuation coefficients. More importantly, the combined application of Zr and Au exerted the catalase-Like activity to alleviate the hypoxic tumor microenvironment by catalyzing the conversion of tumor metabolite H₂O₂ to O₂, which facilitated O₂-dependent radiotherapy. Tian et al. also reported core/satellite-like UiO-66/Au NPs nanohybrids for improving the RT efficiency in the hypoxic triple negative breast cancer by dual CA IX inhibition strategy.^[89] Once the nanohybrid entered tumor cells, the UiO-66 matrix were decomposed by the high concentration of phosphate, releasing p-phthalic acid, the building skeleton of the UiO-66 MOF, to inhibit CA IX. Meanwhile, the Au NPs not only could enhance the radiosensitivity of tumor cells but also effectively load CA IX antisense oligonucleotide (ASO) *via* Au-S bond to knockdown CA IX. These previously integrated functional parts cooperated with each other and played an excellent RT effect in the hypoxic tumor bearing animal model.

3.3. Other types of metal-based nMOFs

A considerable number of nMOFs based on other metal elements have been proven to have effective ra-

metal elements in radiotherapy, a large number of MPNs based on metal elements (e.g., Hafnium, Platinum, Gadolinium) have been prepared to improve therapeutic benefits for radiotherapy.^[39, 96] Dai et al. have done a lot of excellent works in this field. For example, an oxygen-enriched X-ray nanoprocessor based on the Hf-polyphenols coordination (Hb@Hf-Ce6) was developed for improving the therapeutic effect of RT-RDT, enhancing oxygen enrichment in tumor microenvironment and promoting antitumor immune responses when combined with PD-1 immune checkpoint blockade. Given the high-Z metal of Hf not only could promote radiation dose enhancement, but also exhibited superior photoelectric effect, which could be used as favorable light source for RDT. Consequently, abundant ROS was generated and resulted in tumor regression.^[97] Pt-based MPN has also been designed as a platform for relieving tumor hypoxia, which has made good achievements in the field of RT and sonodynamic therapy (SDT). In a nutshell, low-intensity pulsed ultrasound (LIPUS) was performed before radiotherapy to regulate hypoxia levels. Then the prepared PP18-Pt NPs based on the assembly of the PEG-polyphenols encapsulated with radiosensitizers Pt and the sonosensitizer PEG-purpurin 18 were administrated. The radiosensitizer and sonosensitizer were activated *via* controllable LIPUS and RT, producing high concentrations of ROS to kill tumor cells accurately as displayed in Figure 3A.^[98] Besides, based on the robust metal-phenolic coordination of NaGdF₄:Nd@NaLuF₄ and Mn²⁺, they also successfully fabricated a novel lanthanide-doped MPN (DSPM). As shown in Figure 3B, the released radiosensitizer and Mn²⁺ in response to pH sensitized tumor cells to X-ray and promoted STING pathway activation to overcome the radioresistance caused by the immunosuppressive microenvironment after DSPM internalized into cells.^[99]


Figure 3 (A) Illustration of the PP18-Pt NPs mediated radiotherapy enhancement. Reprinted with permission,^[98] Copyright 2022, Wiley-VCH. (B) Illustration of the radiosensitization and immunomodulation effect of lanthanide-doped MPN. Reprinted with permission,^[99] Copyright 2022, Wiley-VCH.

5. Conclusions and Perspectives

In conclusion, the unique properties of nanomaterials, such as the high surface area, stability, and tunability bring opportunities for traditional radiotherapy. Especially, metal-based nanomaterials with the intrinsic radiosensitive activities and chemical inertness in cellular systems exhibit good radiosensitization effects and can be applied to sensitize tumor cells to radiotherapy. The particle size, shape, and surface functionalization of metal-based nanomaterials are well manipulated with the vigorous development of nanotechnology. Therefore, nanoradiosensitizers can be easily synthesized with desirable size and functional modification.^[100] More importantly, profiting from the unique advantages of nano-structure, nanomaterials possess favorable pharmacokinetics profiles and can effectively delivery metal-based radiosensitizers to tumor tissue *via* the active targeting or the enhanced permeability and retention (EPR) effect mediated passive targeting. Currently, many high-Z nanomaterials have entered clinical trials for cancer radiosensitization.^[101-103] In particular, the HfO₂nanoparticles NBTXR3 showed encouraging radiological and pathologic responses in patients with soft tissue sarcoma in clinical trial.^[104-106] Therefore, metal-based nanomaterials are promising radiosensitizers to improve the radiotherapeutic outcome and decrease the side effects, which accelerate the development of nanoradiosensitizers.

Despite the current some achievements, there are still some challenges for metal-based nanoradiosensitizers, such as the potential toxicity of nanoradiosensitizers containing heavy or toxic metals due to the inefficient elimination from body. Compared with small molecule drugs, nanoradiosensitizer has a longer circulation time in the body and is not easy to degrade. Thus, the biocompatibility and long term toxicity of nanoradiosensitizers must be comprehensively investigated before applied to the clinic. Moreover, nanoradiosensitizer lack targeting specificity. In the further, radiosensitizers with highly effective and low toxicity are expected to be exploited for radiotherapy. In conclusion, metal-based nanomaterials are promising radiosensitizers, and more techniques need to be introduced to accelerate the development of metal-based nanoradiosensitization for low dose radiotherapy in clinic.

Acknowledgement



This work was supported by the National Natural Science Foundation of China (nos. 82172762, 21904119, 31900991, 82073395), the Innovation Talent Support Program of Henan Province (no. 21HASTIT043), the Postdoctoral Science Foundation of China (nos. 2020TQ0288, 2021M690140), and the Postdoctoral Innovative Talent Support Program of Henan Province (no. ZYYCYU202012179).

References

- [1] Hwang, W. L.; Pike, L. R. G.; Royce, T. J.; Mahal, B. A.; Loeffler, J. S., Safety of combining radiotherapy with immune-checkpoint inhibition. *Nat Rev Clin Oncol* 2018, 15 (8), 477-494.
- [2] De Martino, M.; Daviaud, C.; Vanpouille-Box, C., Radiotherapy: An immune response modifier for immuno-oncology. *Semin Immunol* 2021, 52, 101474.
- [3] Zhang, D.; Zhong, D.; Ouyang, J.; He, J.; Qi, Y.; Chen, W.; Zhang, X.; Tao, W.; Zhou, M., Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy. *Nat Commun* 2022, 13 (1), 1413.
- [4] Petroni, G.; Cantley, L. C.; Santambrogio, L.; Formenti, S. C.; Galluzzi, L., Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. *Nat Rev Clin Oncol* 2022, 19 (2), 114-131.
- [5] Tang, L.; Wei, F.; Wu, Y.; He, Y.; Shi, L.; Xiong, F.; Gong, Z.; Guo, C.; Li, X.; Deng, H.; Cao, K.; Zhou, M.; Xiang, B.; Li, X.; Li, Y.; Li, G.; Xiong, W.; Zeng, Z., Role of metabolism in cancer cell radioresistance and radiosensitization methods. *J Exp Clin Cancer Res* 2018, 37 (1), 87.
- [6] Su, W.; Wang, H.; Wang, T.; Li, X.; Tang, Z.; Zhao, S.; Zhang, M.; Li, D.; Jiang, X.; Gong, T.; Yang, W.; Zuo, C.; Wu, Y.; Bu, W., Auger Electrons Constructed Active Sites on Nanocatalysts for Catalytic Internal Radiotherapy. *Adv Sci (Weinh)* 2020, 7 (10), 1903585.
- [7] Du, J.; Gu, Z.; Yan, L.; Yong, Y.; Yi, X.; Zhang, X.; Liu, J.; Wu, R.; Ge, C.; Chen, C.; Zhao, Y., Poly(Vinylpyrrolidone)- and Selenocysteine-Modified Bi₂Se₃Nanoparticles Enhance Radiotherapy Efficacy in Tumors and Promote Radioprotection in Normal Tissues. *Adv Mater* 2017, 29 (34).
- [8] Xie, J.; Gong, L.; Zhu, S.; Yong, Y.; Gu, Z.; Zhao, Y., Emerging Strategies of Nanomaterial-Mediated Tumor Radiosensitization. *Adv Mater* 2019, 31 (3), e1802244.
- [9] Buckley, A. M.; Lynam-Lennon, N.; O'Neill, H.; O'Sullivan, J., Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. *Nat Rev Gastroenterol Hepatol* 2020, 17 (5), 298-313.
- [10] Zai, W.; Kang, L.; Dong, T.; Wang, H.; Yin, L.; Gan, S.; Lai, W.; Ding, Y.; Hu, Y.; Wu, J., E. coli Membrane Vesicles as a Catalase Carrier for Long-Term Tumor Hypoxia Relief to Enhance Radiotherapy. *ACS Nano* 2021, 15 (9), 15381-15394.
- [11] Peng, S.; Song, R.; Lin, Q.; Zhang, Y.; Yang, Y.; Luo, M.; Zhong, Z.; Xu, X.; Lu, L.; Yao, S.; Zhang, F., A Robust Oxygen Microbubble Radiosensitizer for Iodine-125 Brachytherapy. *Adv Sci (Weinh)* 2021, 8

(7), 2002567.

[12] Nakamura, K.; Karmokar, A.; Farrington, P. M.; James, N. H.; Ramos-Montoya, A.; Bickerton, S. J.; Hughes, G. D.; Illidge, T. M.; Cadogan, E. B.; Davies, B. R.; Dovedi, S. J.; Valge-Archer, V., Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. *Clin Cancer Res* 2021, 27 (15), 4353-4366.

[13] Wang, Y.; Chen, J.; Duan, R.; Gu, R.; Wang, W.; Wu, J.; Lian, H.; Hu, Y.; Yuan, A., High-Z-Sensitized Radiotherapy Synergizes with the Intervention of the Pentose Phosphate Pathway for In Situ Tumor Vaccination. *Adv Mater* 2022, 34 (13), e2109726.

[14] Fu, W.; Zhang, X.; Mei, L.; Zhou, R.; Yin, W.; Wang, Q.; Gu, Z.; Zhao, Y., Stimuli-Responsive Small-on-Large Nanoradiosensitizer for Enhanced Tumor Penetration and Radiotherapy Sensitization. *ACS Nano* 2020, 14 (8), 10001-10017.

[15] Chan, L.; Chen, X.; Gao, P.; Xie, J.; Zhang, Z.; Zhao, J.; Chen, T., Coordination-Driven Enhancement of Radiosensitization by Black Phosphorus via Regulating Tumor Metabolism. *ACS Nano* 2021, 15 (2), 3047-3060.

[16] Wang, H.; Mu, X.; He, H.; Zhang, X. D., Cancer Radiosensitizers. *Trends Pharmacol Sci* 2018, 39 (1), 24-48.

[17] Nosrati, H.; Seidi, F.; Hosseinmirzaei, A.; Mousazadeh, N.; Mohammadi, A.; Ghaffarlou, M.; Danafar, H.; Conde, J.; Sharafi, A., Prodrug Polymeric Nanoconjugates Encapsulating Gold Nanoparticles for Enhanced X-Ray Radiation Therapy in Breast Cancer. *Adv Healthc Mater* 2022, 11 (3), e2102321.

[18] Liu, L.; Li, Q.; Chen, L.; Song, L.; Zhang, X.; Huo, H.; You, Z.; Wu, Y.; Wu, Z.; Ye, J.; Fu, Q.; Su, L.; Zhang, X.; Yang, H.; Song, J., Plasmon enhanced catalysis-driven nanomotors with autonomous navigation for deep cancer imaging and enhanced radiotherapy. *Chemical Science* 2022, 13 (43), 12840-12850.

[19] Piktel, E.; Oscilowska, I.; Suprewicz, L.; Depciuch, J.; Marcinczyk, N.; Chabielska, E.; Wolak, P.; Wollny, T.; Janion, M.; Parlinska-Wojtan, M.; Bucki, R., ROS-Mediated Apoptosis and Autophagy in Ovarian Cancer Cells Treated with Peanut-Shaped Gold Nanoparticles. *Int J Nanomedicine* 2021, 16, 1993-2011.

[20] Lin, X.; Zhu, R.; Hong, Z.; Zhang, X.; Chen, S.; Song, J.; Yang, H., GSH-Responsive Radiosensitizers with Deep Penetration Ability for Multimodal Imaging-Guided Synergistic Radio-Chemodynamic Cancer Therapy. *Advanced Functional Materials* 2021, 31 (24).

[21] Laurent, G.; Benbalit, C.; Chretien, C.; Dupuis, C.; Pellequer, Y.; Bazzi, R.; Thakare, V. S.; Denat, F.; Roux, S.; Beduneau, A., Characterization and biodistribution of Au nanoparticles loaded in PLGA nanocarriers using an original encapsulation process. *Colloids Surf B Biointerfaces* 2021, 205, 111875.

[22] Hu, P.; Hou, X.; Yu, X.; Wei, X.; Li, Y.; Yang, D.; Jiang, X., Folic Acid-Conjugated Gold Nanostars for Computed Tomography Imaging and Photothermal/Radiation Combined Therapy. *ACS Appl Bio Mater* 2021, 4 (6), 4862-4871.

[23] Das, R. P.; Gandhi, V. V.; Singh, B. G.; Kunwar, A., A pH-controlled one-pot synthesis of gold nanostars by using a zwitterionic protein hydrolysate (gelatin): an enhanced radiosensitization of cancer cells. *New Journal of Chemistry* 2021, 45 (30), 13271-13279.

[24] Sun, W.; Luo, L.; Feng, Y.; Cai, Y.; Zhuang, Y.; Xie, R. J.; Chen, X.; Chen, H., Aggregation-Induced Emission Gold Clustoluminogens for Enhanced Low-Dose X-ray-Induced Photodynamic Therapy. *Angew Chem Int Ed Engl* 2020, 59 (25), 9914-9921.

[25] Luo, D.; Johnson, A.; Wang, X.; Li, H.; Erokku, B. O.; Springer, S.; Lou, J.; Ramamurthy, G.; Flask, C. A.; Burda, C.; Meade, T. J.; Basilion, J. P., Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer. *Nano Lett* 2020, 20 (10), 7159-7167.

- [26] Ding, Y.; Sun, Z.; Tong, Z.; Zhang, S.; Min, J.; Xu, Q.; Zhou, L.; Mao, Z.; Xia, H.; Wang, W., Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. *Theranostics* 2020, 10 (12), 5195-5208.
- [27] Bennie, L.; Belhout, S. A.; Quinn, S. J.; Coulter, J. A., Polymer-Supported Gold Nanoparticle Radiosensitizers with Enhanced Cellular Uptake Efficiency and Increased Cell Death in Human Prostate Cancer Cells. *ACS Applied Nano Materials* 2020, 3 (4), 3157-3162.
- [28] Zhang, Y.; Huang, F.; Ren, C.; Liu, J.; Yang, L.; Chen, S.; Chang, J.; Yang, C.; Wang, W.; Zhang, C.; Liu, Q.; Liang, X. J.; Liu, J., Enhanced Radiosensitization by Gold Nanoparticles with Acid-Triggered Aggregation in Cancer Radiotherapy. *Adv Sci (Weinh)* 2019, 6 (8), 1801806.
- [29] Yang, Y.; Chen, M.; Wang, B.; Wang, P.; Liu, Y.; Zhao, Y.; Li, K.; Song, G.; Zhang, X. B.; Tan, W., NIR-II Driven Plasmon-Enhanced Catalysis for a Timely Supply of Oxygen to Overcome Hypoxia-Induced Radiotherapy Tolerance. *Angew Chem Int Ed Engl* 2019, 58 (42), 15069-15075.
- [30] Pagacova, E.; Stefancikova, L.; Schmidt-Kaler, F.; Hildenbrand, G.; Vicar, T.; Depes, D.; Lee, J. H.; Bestvater, F.; Lacombe, S.; Porcel, E.; Roux, S.; Wenz, F.; Kopečna, O.; Falkova, I.; Hausmann, M.; Falk, M., Challenges and Contradictions of Metal Nano-Particle Applications for Radio-Sensitivity Enhancement in Cancer Therapy. *Int J Mol Sci* 2019, 20 (3).
- [31] Zhang, X.; Chen, X.; Jiang, Y. W.; Ma, N.; Xia, L. Y.; Cheng, X.; Jia, H. R.; Liu, P.; Gu, N.; Chen, Z.; Wu, F. G., Glutathione-Depleting Gold Nanoclusters for Enhanced Cancer Radiotherapy through Synergistic External and Internal Regulations. *ACS Appl Mater Interfaces* 2018, 10 (13), 10601-10606.
- [32] Sun, G.; Wang, T.; Li, X.; Li, D.; Peng, Y.; Wang, X.; Jia, G.; Su, W.; Cheng, C.; Yang, J.; Zuo, C., Sub-Micrometer Au@PDA-(125) I Particles as Theranostic Embolism Beads for Radiosensitization and SPECT/CT Monitoring. *Adv Healthc Mater* 2018, 7 (16), e1800375.
- [33] Goswami, N.; Luo, Z.; Yuan, X.; Leong, D. T.; Xie, J., Engineering gold-based radiosensitizers for cancer radiotherapy. *Materials Horizons* 2017, 4 (5), 817-831.
- [34] Ma, N.; Jiang, Y. W.; Zhang, X.; Wu, H.; Myers, J. N.; Liu, P.; Jin, H.; Gu, N.; He, N.; Wu, F. G.; Chen, Z., Enhanced Radiosensitization of Gold Nanospikes via Hyperthermia in Combined Cancer Radiation and Photothermal Therapy. *ACS Appl Mater Interfaces* 2016, 8 (42), 28480-28494.
- [35] Kaur, H.; Pujari, G.; Semwal, M. K.; Sarma, A.; Avasthi, D. K., In vitro studies on radiosensitization effect of glucose capped gold nanoparticles in photon and ion irradiation of HeLa cells. *Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms* 2013, 301, 7-11.
- [36] Popova, N. P.; Taran, G. S.; Popov, A. L.; Kolmanovich, D. D.; Baranchikov, A. E.; Sorokina, S. S.; Zhizhin, K. Y.; Ivanov, V. K., Selective Radiosensitizing Effect of Amorphous Hafnia Modified with Organic Quantum Dots on Normal and Malignant Cells. *Russian Journal of Inorganic Chemistry* 2021, 66 (6), 931-937.
- [37] Zhang, Y.; Zheng, D.; Talaei, S.; Abasi, M., Albumin stabilized Pt nanoparticles as radiosensitizer for sensitization of breast cancer cells under X-ray radiation therapy. *Inorganic Chemistry Communications* 2022, 140.
- [38] Pan, P.; Dong, X.; Chen, Y.; Zeng, X.; Zhang, X. Z., Engineered Bacteria for Enhanced Radiotherapy against Breast Carcinoma. *ACS Nano* 2022, 16 (1), 801-812.
- [39] Huang, X.; Zha, F.; Zou, J.; Li, Y.; Wang, F.; Chen, X., Photoacoustic Imaging-Guided Synergistic Photothermal/Radiotherapy Using Plasmonic Bi/Bi₂O₃-x Nanoparticles. *Advanced Functional Materials* 2022, 32 (23).
- [40] Chai, R.; Yu, L.; Dong, C.; Yin, Y.; Wang, S.; Chen, Y.; Zhang, Q., Oxygen-evolving photosynthetic

cyanobacteria for 2D bismuthene radiosensitizer-enhanced cancer radiotherapy. *Bioact Mater* 2022, 17, 276-288.

[41] Wang, X.; Guo, Z.; Zhang, C.; Zhu, S.; Li, L.; Gu, Z.; Zhao, Y., Ultrasmall BiOI Quantum Dots with Efficient Renal Clearance for Enhanced Radiotherapy of Cancer. *Adv Sci (Weinh)* **2020**, 7 (6), 1902561.

[42] Liu, H.; Cheng, R.; Dong, X.; Zhu, S.; Zhou, R.; Yan, L.; Zhang, C.; Wang, Q.; Gu, Z.; Zhao, Y., BiO (2-x) Nanosheets as Radiosensitizers with Catalase-Like Activity for Hypoxia Alleviation and Enhancement of the Radiotherapy of Tumors. *Inorg Chem* 2020, 59 (6), 3482-3493.

[43] Zhou, R.; Wang, H.; Yang, Y.; Zhang, C.; Dong, X.; Du, J.; Yan, L.; Zhang, G.; Gu, Z.; Zhao, Y., Tumor microenvironment-manipulated radiocatalytic sensitizer based on bismuth heteropolytungstate for radiotherapy enhancement. *Biomaterials* 2019, 189, 11-22.

[44] Zhao, Z.; Gao, P.; Ma, L.; Chen, T., A highly X-ray sensitive iridium prodrug for visualized tumor radiochemotherapy. *Chem Sci* 2020, 11 (15), 3780-3789.

[45] Wang, L.; Zhang, T.; Huo, M.; Guo, J.; Chen, Y.; Xu, H., Construction of Nucleus-Targeting Iridium Nanocrystals for Photonic Hyperthermia-Synergized Cancer Radiotherapy. *Small* 2019, 15 (47), e1903254.

[46] Feng, L.; Dong, Z.; Liang, C.; Chen, M.; Tao, D.; Cheng, L.; Yang, K.; Liu, Z., Iridium nanocrystals encapsulated liposomes as near-infrared light controllable nanozymes for enhanced cancer radiotherapy. *Biomaterials* 2018, 181, 81-91.

[47] Yin, N.; Wang, Y.; Cao, Y.; Huang, Y.; Jin, L.; Zhang, S.; Liu, J.; Zhang, T.; Lv, Z.; Liu, Y.; Song, S.; Wang, D.; Zhang, H., A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma. *Nano Today* 2022, 46.

[48] Yang, R. Q.; Wang, P. Y.; Lou, K. L.; Dang, Y. Y.; Tian, H. N.; Li, Y.; Gao, Y. Y.; Huang, W. H.; Zhang, Y. Q.; Liu, X. L.; Zhang, G. J., Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy. *Adv Sci (Weinh)* 2022, 9 (12), e2104728.

[49] Liu, R.; Gong, L.; Zhu, X.; Zhu, S.; Wu, X.; Xue, T.; Yan, L.; Du, J.; Gu, Z., Transformable Gallium-Based Liquid Metal Nanoparticles for Tumor Radiotherapy Sensitization. *Adv Healthc Mater* 2022, 11 (11), e2102584.

[50] Ma, X.; Lee, C.; Zhang, T.; Cai, J.; Wang, H.; Jiang, F.; Wu, Z.; Xie, J.; Jiang, G.; Li, Z., Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer. *J Nanobiotechnology* 2021, 19 (1), 284.

[51] Lee, C.; Liu, X.; Zhang, W.; Duncan, M. A.; Jiang, F.; Kim, C.; Yan, X.; Teng, Y.; Wang, H.; Jiang, W.; Li, Z.; Xie, J., Ultrasmall Gd@Cdots as a radiosensitizing agent for non-small cell lung cancer. *Nanoscale* 2021, 13 (20), 9252-9263.

[52] Du, Y.; Sun, H.; Lux, F.; Xie, Y.; Du, L.; Xu, C.; Zhang, H.; He, N.; Wang, J.; Liu, Y.; Leduc, G.; Doussineau, T.; Ji, K.; Wang, Q.; Lin, Z.; Wang, Y.; Liu, Q.; Tillement, O., Radiosensitization Effect of AGuIX, a Gadolinium-Based Nanoparticle, in Non-small Cell Lung Cancer. *ACS Appl Mater Interfaces* 2020, 12 (51), 56874-56885.

[53] Hu, P.; Fu, Z.; Liu, G.; Tan, H.; Xiao, J.; Shi, H.; Cheng, D., Gadolinium-Based Nanoparticles for Theranostic MRI-Guided Radiosensitization in Hepatocellular Carcinoma. *Front Bioeng Biotechnol* 2019, 7, 368.

[54] Ji, C.; Zhao, M.; Wang, C.; Liu, R.; Zhu, S.; Dong, X.; Su, C.; Gu, Z., Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes. *ACS Nano* 2022, 16 (6), 9428-9441.

- [55] Pan, P.; Dong, X.; Chen, Y.; Ye, J. J.; Sun, Y. X.; Zhang, X. Z., A heterogenic membrane-based biomimetic hybrid nanoplatfrom for combining radiotherapy and immunotherapy against breast cancer. *Biomaterials* 2022, 289, 121810.
- [56] Huang, W.; He, L.; Zhang, Z.; Shi, S.; Chen, T., Shape-Controllable Tellurium-Driven Heterostructures with Activated Robust Immunomodulatory Potential for Highly Efficient Radiophotothermal Therapy of Colon Cancer. *ACS Nano* 2021, 15 (12), 20225-20241.
- [57] Yang, R. Q.; Wang, P. Y.; Lou, K. L.; Dang, Y. Y.; Tian, H. N.; Li, Y.; Gao, Y. Y.; Huang, W. H.; Zhang, Y. Q.; Liu, X. L.; Zhang, G. J., Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy. *Advanced Science* 2022, 9 (12).
1. Zhang, Y.; Wang, F.; Liu, C.; Wang, Z.; Kang, L.; Huang, Y.; Dong, K.; Ren, J.; Qu, X., Nanozyme Decorated Metal-Organic Frameworks for Enhanced Photodynamic Therapy. *ACS nano* 2018, 12 (1), 651-661.
 2. Liang, K.; Ricco, R.; Doherty, C. M.; Styles, M. J.; Bell, S.; Kirby, N.; Mudie, S.; Haylock, D.; Hill, A. J.; Doonan, C. J.; Falcaro, P., Biomimetic mineralization of metal-organic frameworks as protective coatings for biomacromolecules. *Nature communications* 2015, 6.
 3. Alsaiani, S. K.; Patil, S.; Alyami, M.; Alamoudi, K. O.; Aleisa, F. A.; Merzaban, J. S.; Li, M.; Khashab, N. M., Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework. *Journal of the American Chemical Society* 2018, 140 (1), 143-146.
 4. Wu, S.; Zhang, K.; Liang, Y.; Wei, Y.; An, J.; Wang, Y.; Yang, J.; Zhang, H.; Zhang, Z.; Liu, J.; Shi, J., Nano-enabled Tumor Systematic Energy Exhaustion via Zinc (II) Interference Mediated Glycolysis Inhibition and Specific GLUT1 Depletion. *Advanced science* 2021, e2103534.
 5. Zhao, X.; Wang, Y.; Jiang, W.; Wang, Q.; Li, J.; Wen, Z.; Li, A.; Zhang, K.; Zhang, Z.; Shi, J.; Liu, J., Herpesvirus-Mimicking DNAzyme-Loaded Nanoparticles as a Mitochondrial DNA Stress Inducer to Activate Innate Immunity for Tumor Therapy. *Advanced materials* 2022, e2204585.
 6. Luo, T.; Nash, G. T.; Xu, Z.; Jiang, X.; Liu, J.; Lin, W., Nanoscale Metal-Organic Framework Confines Zinc-Phthalocyanine Photosensitizers for Enhanced Photodynamic Therapy. *J Am Chem Soc* 2021, 143 (34), 13519-13524.
 7. Dekrafft, K. E.; Boyle, W. S.; Burk, L. M.; Zhou, O. Z.; Lin, W., Zr- and Hf-based nanoscale metal-organic frameworks as contrast agents for computed tomography. *J Mater Chem* 2012, 22 (35), 18139-18144.
 8. Lan, G.; Ni, K.; Veroneau, S. S.; Song, Y.; Lin, W., Nanoscale Metal-Organic Layers for Radiotherapy-Radiodynamic Therapy. *J Am Chem Soc* 2018, 140 (49), 16971-16975.
 9. Lan, G.; Ni, K.; Xu, R.; Lu, K.; Lin, Z.; Chan, C.; Lin, W., Nanoscale Metal-Organic Layers for Deeply Penetrating X-ray-Induced Photodynamic Therapy. *Angew Chem Int Ed Engl* 2017, 56 (40), 12102-12106.
 10. Ni, K.; Lan, G.; Chan, C.; Quigley, B.; Lu, K.; Aung, T.; Guo, N.; La Riviere, P.; Weichselbaum, R. R.; Lin, W., Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. *Nat Commun* 2018, 9 (1), 2351.
 11. Zhou, W.; Liu, Z.; Wang, N.; Chen, X.; Sun, X.; Cheng, Y., Hafnium-Based Metal-Organic Framework Nanoparticles as a Radiosensitizer to Improve Radiotherapy Efficacy in Esophageal Cancer. *ACS Omega* 2022, 7 (14), 12021-12029.
 12. Gong, T.; Li, Y.; Lv, B.; Wang, H.; Liu, Y.; Yang, W.; Wu, Y.; Jiang, X.; Gao, H.; Zheng, X.; Bu, W., Full-Process Radiosensitization Based on Nanoscale Metal-Organic Frameworks. *ACS Nano* 2020, 14 (3), 3032-3040.
 13. Guo, N.; Ni, K.; Luo, T.; Lan, G.; Arina, A.; Xu, Z.; Mao, J.; Weichselbaum, R. R.; Spiotto, M.; Lin, W., Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapy-Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. *ACS Nano* 2021, 15 (11), 17515-17527.
 14. Ni, K.; Luo, T.; Culbert, A.; Kaufmann, M.; Jiang, X.; Lin, W., Nanoscale Metal-Organic Framework

- Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy. *J Am Chem Soc* 2020, 142 (29), 12579-12584.
15. Liu, J.; Yang, Y.; Zhu, W.; Yi, X.; Dong, Z.; Xu, X.; Chen, M.; Yang, K.; Lu, G.; Jiang, L.; Liu, Z., Nanoscale metal-organic frameworks for combined photodynamic & radiation therapy in cancer treatment. *Biomaterials* 2016, 97, 1-9.
16. Ni, K.; Lan, G.; Chan, C.; Duan, X.; Guo, N.; Veroneau, S. S.; Weichselbaum, R. R.; Lin, W., Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. *Matter* 2019, 1 (5), 1331-1353.
17. Lan, G.; Ni, K.; Veroneau, S. S.; Luo, T.; You, E.; Lin, W., Nanoscale Metal-Organic Framework Hierarchically Combines High-Z Components for Multifarious Radio-Enhancement. *J Am Chem Soc* 2019, 141 (17), 6859-6863.
18. Luo, T.; Nash, G. T.; Jiang, X.; Feng, X.; Mao, J.; Liu, J.; Juloori, A.; Pearson, A. T.; Lin, W., A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy. *Adv Mater* 2022, 34 (39), e2110588.
19. Ni, K.; Lan, G.; Veroneau, S. S.; Duan, X.; Song, Y.; Lin, W., Nanoscale metal-organic frameworks for mitochondria-targeted radiotherapy-radiodynamic therapy. *Nat Commun* 2018, 9 (1), 4321.
20. Ni, K.; Lan, G.; Song, Y.; Hao, Z.; Lin, W., Biomimetic nanoscale metal-organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy. *Chem Sci* 2020, 11 (29), 7641-7653.
21. Ni, K.; Lan, G.; Guo, N.; Culbert, A.; Luo, T.; Wu, T.; Weichselbaum, R. R.; Lin, W., Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. *Sci Adv* 2020, 6 (40).
22. Lu, K.; He, C.; Guo, N.; Chan, C.; Ni, K.; Lan, G.; Tang, H.; Pelizzari, C.; Fu, Y. X.; Spiotto, M. T.; Weichselbaum, R. R.; Lin, W., Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. *Nat Biomed Eng* 2018, 2 (8), 600-610.
23. Neufeld, M. J.; DuRoss, A. N.; Landry, M. R.; Winter, H.; Goforth, A. M.; Sun, C., Co-delivery of PARP and PI3K inhibitors by nanoscale metal-organic frameworks for enhanced tumor chemoradiation. *Nano Research* 2019, 12 (12), 3003-3017.
24. Li, D.; Dai, Q.; Chen, H.; Lin, H.; Lu, Z.; Zheng, H.; Lv, P.; Li, W.; Liu, G.; Chu, C., Metal-organic nanostructure based on TixOy/Ruthenium reaction Units: For CT/MR Imaging-Guided X-ray induced dynamic therapy. *Chemical Engineering Journal* 2021, 417.
25. Zhou, X.; Zhang, H.; Wang, L.; Wu, R., An alkali-resistant zirconium-biligand organic framework with dual-metal centers for highly selective capture of phosphopeptides. *Analyst* 2022.
26. Ji, P.; Manna, K.; Lin, Z.; Feng, X.; Urban, A.; Song, Y.; Lin, W., Single-Site Cobalt Catalysts at New Zr(12)(mu(3)-O)(8)(mu(3)-OH)(8)(mu(2)-OH)(6) Metal-Organic Framework Nodes for Highly Active Hydrogenation of Nitroarenes, Nitriles, and Isocyanides. *J Am Chem Soc* 2017, 139 (20), 7004-7011.
27. Gong, W.; Zhang, W.; Son, F. A.; Yang, K.; Chen, Z.; Chen, X.; Jiang, J.; Liu, Y.; Farha, O. K.; Cui, Y., Topological Strain-Induced Regioselective Linker Elimination in a Chiral Zr(IV)-Based Metal-Organic Framework. *Chem* 2021, 7 (1), 190-201.
28. Fang, H.; Zheng, B.; Zhang, Z. H.; Li, H. X.; Xue, D. X.; Bai, J., Ligand-Conformer-Induced Formation of Zirconium-Organic Framework for Methane Storage and MTO Product Separation. *Angew Chem Int Ed Engl* 2021, 60 (30), 16521-16528.
29. Dai, Q.; Wang, L.; Ren, E.; Chen, H.; Gao, X.; Cheng, H.; An, Y.; Chu, C.; Liu, G., Ruthenium-Based Metal-Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release. *Angew Chem Int Ed Engl* 2022, 61 (50), e202211674.
30. Ma, T.; Liu, Y.; Wu, Q.; Luo, L.; Cui, Y.; Wang, X.; Chen, X.; Tan, L.; Meng, X., Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX. *ACS Nano* 2019, 13 (4), 4209-4219.
31. He, Z.; Huang, X.; Wang, C.; Li, X.; Liu, Y.; Zhou, Z.; Wang, S.; Zhang, F.; Wang, Z.; Jacobson, O.; Zhu, J. J.; Yu, G.; Dai, Y.; Chen, X., A Catalase-Like Metal-Organic Framework Nanohybrid for O(2)-Evolving Synergistic Chemoradiotherapy. *Angew Chem Int Ed Engl* 2019, 58 (26), 8752-8756.
32. Wang, K.; Ding, S.; Zeng, L.; Zhou, J.; Cao, Y.; Wu, J.; Lu, L.; Bian, X.-w.; Tian, G., Antisense oligonucleotides-Laden UiO-66@Au nanohybrid for enhanced radiotherapy against hypoxic tumor by

- dual-inhibition of carbonic anhydrase IX. *Applied Materials Today* 2021, 25.
33. Zheng, X.; Zhong, J.; Dong, M.-Y.; Wen, Y.; Chen, A.-Z., Synthesis of porphyrin-based 2D ytterbium metal organic frameworks for efficient photodynamic therapy. *RSC Advances* 2022, 12 (53), 34318-34324.
34. Collet, G.; Hrvat, A.; Eliseeva, S. V.; Besnard, C.; Kovalenko, A.; Petoud, S., A near-infrared emitting MOF: controlled encapsulation of a fluorescein sensitizer at the time of crystal growth. *Chem Commun (Camb)* 2021, 57 (27), 3351-3354.
35. Lan, G.; Ni, K.; Veroneau, S. S.; Feng, X.; Nash, G. T.; Luo, T.; Xu, Z.; Lin, W., Titanium-Based Nanoscale Metal-Organic Framework for Type I Photodynamic Therapy. *J Am Chem Soc* 2019, 141 (10), 4204-4208.
36. Xu, Z.; Luo, T.; Mao, J.; McCleary, C.; Yuan, E.; Lin, W., Monte Carlo Simulation-Guided Design of a Thorium-Based Metal-Organic Framework for Efficient Radiotherapy-Radiodynamic Therapy. *Angew Chem Int Ed Engl* 2022, 61 (46), e202208685.
37. Ni, K.; Xu, Z.; Culbert, A.; Luo, T.; Guo, N.; Yang, K.; Pearson, E.; Preusser, B.; Wu, T.; La Riviere, P.; Weichselbaum, R. R.; Spiotto, M. T.; Lin, W., Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. *Nat Biomed Eng* 2022, 6 (2), 144-156.
38. Zhang, H.; Ye, K.; Huang, X.; Lin, X.; Ma, L.; Chen, T., Designing lanthanide coordination nanoframeworks as X-ray responsive radiosensitizers for efficient cancer therapy. *Inorganic Chemistry Frontiers* 2021, 8 (14), 3433-3439.
39. Sang, W.; Zhang, Z.; Wang, G.; Xie, L.; Li, J.; Li, W.; Tian, H.; Dai, Y., A Triple-Kill Strategy for Tumor Eradication Reinforced by Metal-Phenolic Network Nanopumps. *Advanced Functional Materials* 2022, 32 (21).
40. Sang, W.; Xie, L.; Wang, G.; Li, J.; Zhang, Z.; Li, B.; Guo, S.; Deng, C. X.; Dai, Y., Oxygen-Enriched Metal-Phenolic X-Ray Nanoprocessor for Cancer Radio-Radiodynamic Therapy in Combination with Checkpoint Blockade Immunotherapy. *Adv Sci (Weinh)* 2021, 8 (4), 2003338.
41. Tian, Y.; Sang, W.; Tian, H.; Xie, L.; Wang, G.; Zhang, Z.; Li, W.; Dai, Y., A Two-Step Flexible Ultrasound Strategy to Enhance Tumor Radiotherapy via Metal-Phenolic Network Nanoplatfrom. *Advanced Functional Materials* 2022, 32 (36).
42. Yan, J.; Wang, G.; Xie, L.; Tian, H.; Li, J.; Li, B.; Sang, W.; Li, W.; Zhang, Z.; Dai, Y., Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy. *Adv Mater* 2022, 34 (10), e2105783.
43. Choi, J.; Kim, G.; Cho, S. B.; Im, H. J., Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme. *J Nanobiotechnology* 2020, 18 (1), 122.
44. Hu, P.; Cheng, D.; Huang, T.; Banizs, A. B.; Xiao, J.; Liu, G.; Chen, Q.; Wang, Y.; He, J.; Shi, H., Evaluation of Novel (64)Cu-Labeled Theranostic Gadolinium-Based Nanoprobe in HepG2 Tumor-Bearing Nude Mice. *Nanoscale Res Lett* 2017, 12 (1), 523.
45. Wozny, A. S.; Aloy, M. T.; Alphonse, G.; Magne, N.; Janier, M.; Tillement, O.; Lux, F.; Beuve, M.; Rodriguez-Lafrasse, C., Gadolinium-based nanoparticles as sensitizing agents to carbon ions in head and neck tumor cells. *Nanomedicine* 2017, 13 (8), 2655-2660.
46. Le Pechoux, C.; Kantor, G.; Deutsch, E.; Sargos, P.; Levy, A.; De Baere, T.; Buy, X.; Martinetti, F.; Stoeckle, E.; Terrier, P.; Le Cesne, A.; Italiano, A.; Soria, J. C.; Bonvalot, S., PD-0045: Ph I/II study evaluating the impact of nanoparticules combined to pre-operative radiotherapy in soft tissue sarcoma. *Radiotherapy and Oncology* 2015, 115, S21-S22.
47. Bonvalot, S.; Le Pechoux, C.; De Baere, T.; Kantor, G.; Buy, X.; Stoeckle, E.; Terrier, P.; Sargos, P.; Coindre, J. M.; Lassau, N.; Sarkouh, R. A.; Dimitriu, M.; Borghi, E.; Levy, L.; Deutsch, E.; Soria, J.-C., First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. *Clinical Cancer Research* 2017, 23 (4), 908-917.
48. Bonvalot, S.; Rutkowski, P. L.; Thariat, J.; Carrère, S.; Ducassou, A.; Sunyach, M.-P.; Agoston, P.; Hong, A.; Mervoyer, A.; Rastrelli, M.; Moreno, V.; Li, R. K.; Tiangco, B.; Herraiez, A. C.; Gronchi,

- A.; Mangel, L.; Sy-Ortin, T.; Hohenberger, P.; de Baère, T.; Le Cesne, A.; Helfre, S.; Saada-Bouزيد, E.; Borkowska, A.; Anghel, R.; Co, A.; Gebhart, M.; Kantor, G.; Montero, A.; Loong, H. H.; Vergés, R.; Lapeire, L.; Dema, S.; Kacso, G.; Austen, L.; Moureau-Zabotto, L.; Servois, V.; Wardelmann, E.; Terrier, P.; Lazar, A. J.; Bovée, J. V. M. G.; Le Péchoux, C.; Papai, Z., NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. *The Lancet Oncology* 2019, 20 (8), 1148-1159.
49. Haas, R. L.; Miah, A. B.; LePechoux, C.; DeLaney, T. F.; Baldini, E. H.; Alektiar, K.; O’Sullivan, B., Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. *Radiother Oncol* 2016, 119 (1), 14-21.

Recent progress on metal-based nanomaterials for cancer radiosensitization Xiu Zhao, Jun Li, Qiongwei Wang, Z
Metal-based nanomaterials amplify the damage of DNA directly, or produce more ROS by dissociating water to enhance the
